This multicenter, prospective, group-controlled study for early cancer detection is intended to verify whether a new blood test is suitable for distinguishing malignant tumours (cancers) from other tumories/diseases and control subjects.
The AFORCE-1 study aims to test the accuracy of this blood test before it can later be used in diagnostics. This includes patients with suspected tumours (10 most common types of tumours) and healthy volunteers. The development of suspected tumours is observed over a period of 12 months and compared with the results of the blood test for early cancer detection at the end of the study.
The study was rated positively on 05.04.2024 by the Colorectal Cancer Study Board of the German Cancer Society. It therefore meets the criteria for recognition of the study within the certification system and is included in studybox (www.studybox.de) listed. The registration number is: ST-U178.